Literature DB >> 21664702

Cytokine mRNA expression of pulmonary macrophages varies with challenge but not with disease state in horses with heaves or in controls.

Philippe Joubert1, Marie-Eve Cordeau, Jean-Pierre Lavoie.   

Abstract

Heaves in horses is characterized by lower airway neutrophilic inflammation, and reversible airflow obstruction. Pulmonary macrophages contribute to the inflammation observed in a number of human and animal pulmonary diseases, and it has been postulated that they are responsible for the neutrophilic inflammation present in heaves by the release of cytokines and chemokines. To test this hypothesis, the mRNA expression of TNF-α, IL-1β, IL-8, and MIP-2 by macrophages isolated from bronchoalveolar lavage cells was quantified using real-time RT-PCR in horses with heaves (n-6) and controls (n-6). Animals were studied after being pastured for 3 months to induce clinical remission of heaves, and after 24h, and 9 days of a continuous natural antigen challenge consisting of hay feeding and straw bedding. The study was performed during 2 consecutive summers, when 3 horses with heaves and 3 control horses were evaluated. As expected, airway obstruction developed with the challenge only in horses with heaves, while airway neutrophilia was observed in both groups of horses. Stabling resulted in an increased expression of IL-8/ß-actin and MIP-2/ß-actin after 24h of stabling in both groups of horses. Further analyses revealed that compared to pasture, the expression of these chemokines was significantly increased after 24h of stabling only in Year 1, while the IL-8 expression was significantly decreased at 9 days in Year 2. No significant group, time, or year differences in IL-1β/ß-actin and TNF-α/ß-actin ratio were observed. The expression of IL-1β was strongly correlated with neutrophil percentages, although at different time points in the two study-years. These results suggest that alveolar macrophages can contribute to the airway inflammation resulting from stabling in horses by the release of IL-8 and MIP-2, but that the release of these chemokines is unlikely to be responsible for the marked airway neutrophilia observed in heaves. The variable expression of IL-8 and MIP-2 by alveolar macrophages between the two-study years are additional novel findings highlighting the complexity of the inflammatory pathways associated with airway inflammation and the importance of evaluating concurrently horses with heaves and controls to ensure identical environmental challenges.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21664702     DOI: 10.1016/j.vetimm.2011.05.022

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  5 in total

1.  Alveolar macrophage phenotypes in severe equine asthma.

Authors:  M E Wilson; E E McCandless; M A Olszewski; N Edward Robinson
Journal:  Vet J       Date:  2020-02-11       Impact factor: 2.688

2.  Differential gene expression and Ingenuity Pathway Analysis of bronchoalveolar lavage cells from horses with mild/moderate neutrophilic or mastocytic inflammation on BAL cytology.

Authors:  Kaori Uchiumi Davis; M Katie Sheats
Journal:  Vet Immunol Immunopathol       Date:  2021-02-04       Impact factor: 2.046

3.  Tamoxifen inhibits chemokinesis in equine neutrophils.

Authors:  Natalia Morales; Claudio Henriquez; Jose Sarmiento; Benjamin Uberti; Gabriel Moran
Journal:  Ir Vet J       Date:  2018-10-23       Impact factor: 2.146

4.  Flow cytometric analysis of equine bronchoalveolar lavage fluid cells in horses with and without severe equine asthma.

Authors:  Heng Kang; Dorothee Bienzle; Gary Kwok Cheong Lee; Érica Piché; Laurent Viel; Solomon Olawole Odemuyiwa; Janet Beeler-Marfisi
Journal:  Vet Pathol       Date:  2021-09-14       Impact factor: 2.221

Review 5.  The Immune Mechanisms of Severe Equine Asthma-Current Understanding and What Is Missing.

Authors:  Joana Simões; Mariana Batista; Paula Tilley
Journal:  Animals (Basel)       Date:  2022-03-16       Impact factor: 2.752

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.